Skip to main content

A staff member at the Overdose Prevention Site points to a red line indicating a positive result for fentanyl after testing a sample of heroine with recently available test strips in Vancouver, B.C., on Aug. 28, 2017.

Rafal Gerszak/Rafal Gerszak

A pilot project that allows Vancouver drug users to test substances for the deadly opioid fentanyl is being expanded in an effort to reduce overdose deaths.

Vancouver Coastal Health says the pilot project found that clients who found fentanyl in their drugs were 10 times more likely to reduce their dose and, as a result, they were 25 per cent less likely to overdose.

The initiative launched at Insite, a supervised drug-use site, in July, 2016, in response to the crisis that has killed hundreds of people in the province.

Story continues below advertisement

To date, more than 1,400 tests have been conducted.

The health authority says 80 per cent of all drugs tested were positive for fentanyl, including 84 per cent of heroin samples and 65 per cent of non-opiate drugs, such as crystal meth, ecstasy and cocaine.

The check involves dipping a test strip into a drug sample that has been diluted with a few drops of water, revealing a positive or negative result within seconds.

The free drug-checking service will now be available at any of the city's four overdose-prevention sites and the Powell Street Getaway safe-injection site.

Judy Darcy, British Columbia's Minister of Mental Health and Addictions, said the drug test empowers users to make informed decisions about whether or how much they consume.

"At the provincial level, we are actively looking at how we might roll out such drug-checking services more broadly. The information being gathered by Vancouver Coastal Health with this project will be invaluable to this work," she said in a news release.

Report an error
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

If your comment doesn't appear immediately it has been sent to a member of our moderation team for review

Read our community guidelines here

Discussion loading…

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.